Application of streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of product for treating amygdalitis

Abstract

The invention discloses application of a streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of a product for treating amygdalitis. The preservation number of the streptococcus salivarius subsp. Thermophilus Biohalo 23 is DSM34540. The invention further discloses a preparation method of the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet. The streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet can relieve the disease symptoms of amygdalitis, has a remarkable curative effect on amygdalitis, specifically, through clinical tests, the number of people uncomfortable in the whole body, the number of people with low fever and the number of people with lymphadenectasis can be remarkably reduced, meanwhile, the number of white blood cells and the content of C-reactive protein in blood can be reduced, and the treatment effect on amygdalitis is improved. Therefore, the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for treating the amygdalitis.

Description

Technical Field

[0001] The invention relates to the technical field of probiotics, and in particular to application of a Streptococcus salivarius thermophilic subspecies Biohalo23 tablet in the preparation of a product for treating tonsillitis. Background Art

[0002] Tonsillitis is mainly caused by pathogenic microorganisms, such as bacteria and viruses, and the infection source is easily accumulated in the tonsils. This disease is divided into two types: acute and chronic. The incidence rate is high and it is particularly common in spring and autumn. The high-risk groups mainly include children and adolescents.

[0003] The main symptoms of tonsillitis include fever, throat pain, dysphagia, etc. In severe cases, it may even affect sleep and breathing. Acute tonsillitis is contagious and is often accompanied by symptoms of upper respiratory tract infection such as cough and runny nose.

[0004] Virus-induced tonsillitis usually does not require medication and recovers within two weeks. Tonsillitis caused by bacteria should be treated with pathogen-sensitive antibiotics as soon as possible to avoid subsequent complications. Severe chronic tonsillitis may require surgery.

[0005] Untreated or incompletely treated tonsillitis may lead to various complications, such as rhinitis, sinusitis or pharyngitis. Severe complications such as rheumatic heart disease and acute glomerulonephritis may also occur. The prognosis of tonsillitis depends on the severity of the disease and the treatment. Generally, the prognosis of tonsillitis is good if it is treated promptly and correctly.

[0006] Currently, viral tonsillitis can generally be cured without drug treatment. Tonsillitis caused by bacteria is best treated with antibiotics to avoid subsequent complications. Incompletely treated acute tonsillitis can develop into chronic tonsillitis with repeated attacks, and in severe cases, it can progress to purulent tonsillitis. However, antibiotic treatment can easily lead to drug resistance in pathogenic bacteria, which may result in ineffective antibiotic treatment in the event of future infection.

[0007] In view of this, the present invention is proposed. Summary of the invention

[0008] The purpose of the present invention is to provide an application of a thermophilic Streptococcus salivarius subsp. Biohalo23 tablet in the preparation of a product for treating tonsillitis. The thermophilic Streptococcus salivarius subsp. Biohalo23 tablet of the present invention can alleviate the symptoms of tonsillitis and has a significant therapeutic effect on tonsillitis.

[0009] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0010] A first aspect of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in the preparation of a product for treating tonsillitis, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0011] The second aspect of the present invention provides a probiotic tablet, which comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0012] Preferably, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0013] Preferably, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0014] Preferably, the auxiliary materials consist of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0015] Preferably, the flavor includes strawberry flavor, apple flavor or orange flavor.

[0016] Preferably, the mass of each probiotic tablet is 0.9-1 g.

[0017] Compared with the prior art, the beneficial effects of the present invention include at least:

[0018] The thermophilic subspecies of Streptococcus salivarius Biohalo23 tablet of the present invention can relieve the symptoms of tonsillitis and has a significant therapeutic effect on tonsillitis. Specifically, through clinical trials, the number of patients with general discomfort, low fever and swollen lymph nodes can be significantly reduced, and the number of white blood cells and the content of C-reactive protein in the blood can also be reduced, which further indicates that the thermophilic subspecies of Streptococcus salivarius Biohalo23 tablet of the present invention can be used for the treatment of tonsillitis.

[0019] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects. DETAILED DESCRIPTION

[0020] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0021] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the present invention belongs.

[0022] The embodiment of the present invention provides an application of a Streptococcus salivarius thermophilus subspecies Biohalo23 tablet in preparing a product for treating tonsillitis, wherein the Streptococcus salivarius thermophilus subspecies Biohalo23 has a deposit number of DSM34540.

[0023] The preservation unit of the thermophilic subspecies Biohalo23 of Streptococcus salivarius of the present invention is the German Microorganisms Preservation Center, and the strain can be purchased from the German Microorganisms Preservation Center.

[0024] The thermophilic subspecies of Streptococcus salivarius Biohalo23 tablet of the present invention can relieve the symptoms of tonsillitis and has a significant therapeutic effect on tonsillitis. Specifically, through clinical trials, the number of patients with general discomfort, low fever and swollen lymph nodes can be significantly reduced, and the number of white blood cells and the content of C-reactive protein in the blood can also be reduced, which further indicates that the thermophilic subspecies of Streptococcus salivarius Biohalo23 tablet of the present invention can be used for the treatment of tonsillitis.

[0025] In addition, the thermophilic subspecies Biohalo23 tablets of Streptococcus salivarius of the present invention are easy to take and can ensure that the probiotics are stable and active for a long time. At the same time, the special tablets have a stable melting speed, melting in the mouth in about 3-5 minutes, ensuring that there is enough time for the thermophilic subspecies Biohalo23 strain of Streptococcus salivarius to colonize in the oropharynx. However, other dosage forms have poor therapeutic effects, such as liquid preparations, which quickly reach the stomach and intestines when taken, causing the death of a large number of bacteria in the gastrointestinal environment, and fewer strains are colonized in the oropharynx, resulting in failure to achieve effective therapeutic effects.

[0026] Another embodiment of the present invention provides a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials.

[0027] By adding auxiliary materials, the activity of the thermophilic subspecies of Streptococcus salivarius Biohalo23 can be better preserved, and the taste of the product can be improved, thereby improving the taste of the probiotic tablets for children.

[0028] In one embodiment, the content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

[0029] By limiting the content of the thermophilic subspecies Biohalo23 of Streptococcus salivarius in probiotic tablets, the efficacy of the probiotic tablets can be better improved.

[0030] In one embodiment, the auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

[0031] In some embodiments, the auxiliary materials are composed of 10-15 parts of crystalline fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

[0032] In one embodiment, the flavor includes strawberry flavor; in other embodiments, the flavor may be strawberry flavor, apple flavor or orange flavor.

[0033] In one embodiment, the mass of each probiotic tablet is 0.9-1 g.

[0034] The technical scheme of the present invention is further described in detail below through specific examples. The various materials and reagents used in the following specific examples are commonly used materials and reagents in the field and can be obtained through regular commercial channels; the methods used are conventional methods known to those skilled in the art.

[0035] Example 1

[0036] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0037] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0038] The auxiliary materials consist of 10 parts of crystalline fructose, 88 parts of maltodextrin, 0.8 parts of magnesium stearate and 0.2 parts of flavor, wherein the flavor is strawberry flavor.

[0039] Example 2

[0040] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0041] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0042] The auxiliary materials consist of 15 parts of crystalline fructose, 82 parts of maltodextrin, 1.2 parts of magnesium stearate and 0.8 parts of flavor, wherein the flavor is strawberry flavor.

[0043] Example 3

[0044] This embodiment is a probiotic tablet, which includes the thermophilic Streptococcus salivarius subspecies Biohalo23 and auxiliary materials;

[0045] The content of Streptococcus salivarius thermophilus subspecies Biohalo23 in each probiotic tablet is 1 billion cfu, and the mass of each probiotic tablet is 0.95g;

[0046] The auxiliary materials consist of 12 parts of crystalline fructose, 85.5 parts of maltodextrin, 1 part of magnesium stearate and 0.5 parts of flavor, wherein the flavor is strawberry flavor.

[0047] Experimental example

[0048] This experimental example is a study on the effect of Streptococcus salivarius thermophilus subspecies Biohalo23 (German strain bank deposit number DSM34540) on tonsillitis;

[0049] The probiotic tablets used in the following experiments are the probiotic tablets prepared in Example 3.

[0050] 54 children with chronic tonsillitis exacerbated more than twice in one year were recruited and received conservative treatment with nasal irrigation. About 70% of the children had symptoms of swollen tonsils when they were enrolled.

[0051] All children took probiotic tablets for 30 days in May and September, one tablet per day, and the observation period was 180 consecutive days from the start of taking probiotic tablets. Multiple clinical symptoms or test indicators of chronic tonsillitis gradually improved over time, mainly including:

[0052] The number of patients with enlarged tonsils decreased by 14% and 52% at 30 and 180 days, respectively (P<0.05);

[0053] The number of people with general discomfort decreased by 57% and 74%, respectively (P<0.05);

[0054] The number of people with low fever decreased by 88% and 80%, respectively (P<0.05);

[0055] The number of patients with palpable lymphadenopathy decreased by 23% and 47%, respectively (P<0.05);

[0056] The number of patients with leukocytosis decreased by 89% and 87%, respectively (P<0.05);

[0057] The number of people with increased C-reactive protein decreased by 97% and 97%, respectively (P<0.05);

[0058] The number of patients with allergic symptoms caused by aggravated tonsillitis decreased by 82% and 100% respectively (P<0.05).

[0059] In summary, taking probiotic tablets can significantly reduce the number of people with general discomfort, low fever and swollen lymph nodes, and can also reduce the number of white blood cells and C-reactive protein content in the blood, which further indicates that the thermophilic subspecies of Streptococcus salivarius Biohalo23 tablets of the present invention can be used for the treatment of tonsillitis.

[0060] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. Application of Streptococcus salivarius thermophilus subspecies Biohalo23 tablets in the preparation of products for treating tonsillitis, characterized in that: The deposit number of the thermophilic Streptococcus salivarius subspecies Biohalo23 is DSM34540.

2. A probiotic tablet, characterized in that: The probiotic tablet comprises the thermophilic Streptococcus salivarius subspecies Biohalo23 according to claim 1 and auxiliary materials.

3. The probiotic tablet according to claim 2, characterized in that The content of the thermophilic Streptococcus salivarius subspecies Biohalo23 in each probiotic tablet is not less than 500 million cfu.

4. The probiotic tablet according to claim 2, characterized in that The auxiliary materials include crystalline fructose, maltodextrin, magnesium stearate and flavors.

5. The probiotic tablet according to claim 2, characterized in that: The auxiliary material consists of 10-15 parts of crystal fructose, 82-88 parts of maltodextrin, 0.8-1.2 parts of magnesium stearate and 0.2-0.8 parts of flavor.

6. The probiotic tablet according to claim 4, characterized in that: The flavor includes strawberry flavor, apple flavor or orange flavor.

7. The probiotic tablet according to claim 2, characterized in that: The mass of each probiotic tablet is 0.9-1g.